{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:37:20Z","timestamp":1791405440562,"version":"4.3.3"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":277,"URL":"https:\/\/www.nationalarchives.gov.uk\/doc\/open-government-licence\/version\/3\/"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Two monoclonal antibodies directed to the V antigen of Yersinia pestis have been tested for protective efficacy in a murine model of bubonic plague. Mice were infected with a current clinical isolate from Madagascar, designated Y. pestis 10\u201321\/S. Mab7.3, delivered to mice intra-periteoneally at either 24 h prior to, or 24 h post-infection, was fully protective, building on many studies which have demonstrated the protective efficacy of this Mab against a number of different clinical isolates of Y. pestis. Mab 29.3, delivered intra-peritoneally at either \u221224 h or +24 h, protected 4\/5 mice in either condition; this has demonstrated the protective efficacy of this Mab in vivo for the first time. These results add to the cumulative data about Mab7.3, which is currently being humanized and highlight its potential as a human immunotherapeutic for plague, which is an enduring endemic disease in Madagascar and other regions of Africa, Asia, and South America.<\/jats:p>","DOI":"10.1093\/immadv\/ltab020","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T22:30:00Z","timestamp":1633473000000},"source":"Crossref","is-referenced-by-count":7,"title":["Potential human immunotherapeutics for plague"],"prefix":"10.1093","volume":"1","author":[{"given":"Voahangy","family":"Andrianaivoarimanana","sequence":"first","affiliation":[{"name":"Institut Pasteur de Madagascar , BP1274 Ambatofotsikely, Antananarivo-101 , Madagascar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovasoa Nomena","family":"Randriantseheno","sequence":"additional","affiliation":[{"name":"Institut Pasteur de Madagascar , BP1274 Ambatofotsikely, Antananarivo-101 , Madagascar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer M","family":"Moore","sequence":"additional","affiliation":[{"name":"CBR Division, Defence Science and Technology Laboratory , Porton Down, Salisbury , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola J","family":"Walker","sequence":"additional","affiliation":[{"name":"CBR Division, Defence Science and Technology Laboratory , Porton Down, Salisbury , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G","family":"Lonsdale","sequence":"additional","affiliation":[{"name":"CBR Division, Defence Science and Technology Laboratory , Porton Down, Salisbury , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kempster","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Diagnostics, NIBSC Medicines and Healthcare products Regulatory Agency , Blanche Lane, South Mimms , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil A","family":"Almond","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Diagnostics, NIBSC Medicines and Healthcare products Regulatory Agency , Blanche Lane, South Mimms , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoarisoa","family":"Rajerison","sequence":"additional","affiliation":[{"name":"Institut Pasteur de Madagascar , BP1274 Ambatofotsikely, Antananarivo-101 , Madagascar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-5972","authenticated-orcid":false,"given":"E Diane","family":"Williamson","sequence":"additional","affiliation":[{"name":"CBR Division, Defence Science and Technology Laboratory , Porton Down, Salisbury , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"issue":"8","key":"2022062118034414800_CIT0001","first-page":"89","article-title":"Plague around the world, 2010\u20132015","volume":"91","author":"World Health Organization","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"key":"2022062118034414800_CIT0002","year":"2017"},{"issue":"3","key":"2022062118034414800_CIT0003","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/infdis\/126.3.235","article-title":"Effects of fraction I from Yersinia pestis on phagocytosis in vitro","volume":"126","author":"Williams","year":"1972","journal-title":"J Infect Dis"},{"issue":"5748","key":"2022062118034414800_CIT0004","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.1118476","article-title":"The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles","volume":"310","author":"Mueller","year":"2005","journal-title":"Science"},{"issue":"1","key":"2022062118034414800_CIT0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-019-0105-9","article-title":"Plague vaccine: recent progress and prospects","volume":"4","author":"Sun","year":"2019","journal-title":"npj Vaccines"},{"key":"2022062118034414800_CIT0006","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.micpath.2006.09.003","article-title":"Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates","volume":"42","author":"Williamson","year":"2007","journal-title":"Microb Pathogen"},{"issue":"11","key":"2022062118034414800_CIT0007","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1128\/iai.65.11.4476-4482.1997","article-title":"Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization","volume":"65","author":"Hill","year":"1997","journal-title":"Infect Immun"},{"issue":"4","key":"2022062118034414800_CIT0008","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1128\/IAI.71.4.2234-2238.2003","article-title":"Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis","volume":"71","author":"Hill","year":"2003","journal-title":"Infect Immun"},{"issue":"2","key":"2022062118034414800_CIT0009","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.vaccine.2010.08.099","article-title":"TNFa and IFNg contribute to F1\/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague","volume":"29","author":"Lin","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"2022062118034414800_CIT0010","first-page":"2234","article-title":"Binding sites of anti-Lcr V monoclonal antibodies are more critical than the avidities and affinities for passive protection against Yersinia pestis infection in a bubonic plague model","volume":"71","author":"Amemiya","year":"2003","journal-title":"Antibodies (Basel)"},{"issue":"21","key":"2022062118034414800_CIT0011","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/j.vaccine.2009.03.011","article-title":"Small protective fragments of the Yersinia pestis V antigen","volume":"279","author":"Vernazza","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"2022062118034414800_CIT0012","first-page":"301","article-title":"The structure of Yersinia pestis V-antigen, an essential virulence factor and mediator of immunity against plague","volume":"12","author":"Derewenda","year":"2004","journal-title":"Structure"},{"issue":"50","key":"2022062118034414800_CIT0013","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1016\/j.vaccine.2009.09.061","article-title":"N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection","volume":"27","author":"Hill","year":"2009","journal-title":"Vaccine"},{"key":"2022062118034414800_CIT0014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bios.2014.09.090","article-title":"Kinetic epitope mapping of monoclonal antibodies raised against the Yersinia pestis virulence factor LcrV","volume":"65","author":"Read","year":"2015","journal-title":"Biosensors and Bioelectronics"},{"issue":"5","key":"2022062118034414800_CIT0015","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1128\/CVI.00013-14","article-title":"Direct neutralisation of type III effector translocation by the variable region of a Mab to Y. pestis LCRV","volume":"21","author":"Ivanov","year":"2015","journal-title":"Clin Vacc Immunol"},{"key":"2022062118034414800_CIT0016","doi-asserted-by":"crossref","first-page":"Article 1668","DOI":"10.3389\/fimmu.2017.01668","article-title":"The future of immunotherapy: a 20-year perspective","volume":"8","author":"Wraith David","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"2022062118034414800_CIT0017","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s10620-019-05516-7","article-title":"Immunotherapy: current status and future perspectives","volume":"64","author":"Floudas","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"11","key":"2022062118034414800_CIT0018","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"16","key":"2022062118034414800_CIT0019","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N. Engl J Med"},{"issue":"16","key":"2022062118034414800_CIT0020","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/0264-410X(95)00090-N","article-title":"A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model","volume":"13","author":"Russell","year":"1995","journal-title":"Vaccine"},{"issue":"1","key":"2022062118034414800_CIT0021","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4269\/ajtmh.1994.51.109","article-title":"Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona","volume":"51","author":"Doll","year":"1994","journal-title":"Am J Trop Med Hyg"},{"key":"2022062118034414800_CIT0022","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0035-9203(96)90420-4","article-title":"Comparison of Yersinia CIN agar and mouse inoculation assay for the diagnosis of plague","volume":"90","author":"Rasoamanana","year":"1996","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1\u20132","key":"2022062118034414800_CIT0023","first-page":"18","article-title":"La s\u00e9rologie anti-F1 chez la souris OF1, test compl\u00e9mentaire pour le diagnostic de la peste humaine","volume":"64","author":"Dromigny","year":"1998","journal-title":"Arch Inst Pasteur Madagascar"}],"container-title":["Immunotherapy Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/immunotherapyadv\/advance-article-pdf\/doi\/10.1093\/immadv\/ltab020\/40810194\/ltab020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/1\/1\/ltab020\/44157633\/ltab020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/1\/1\/ltab020\/44157633\/ltab020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T18:06:34Z","timestamp":1655834794000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article\/doi\/10.1093\/immadv\/ltab020\/6381612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/immadv\/ltab020","relation":{},"ISSN":["2732-4303"],"issn-type":[{"value":"2732-4303","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2021,1,1]]},"article-number":"ltab020"}}